

Oriol Sibila Vidal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4709752/publications.pdf>

Version: 2024-02-01

128
papers

4,692
citations

126907

33
h-index

114465

63
g-index

134
all docs

134
docs citations

134
times ranked

6257
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 677.	7.4	428
2	Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?. <i>Lancet Respiratory Medicine</i> , 2020, 8, 436-438.	10.7	314
3	Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1384-1393.	5.6	232
4	Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 117-127.	2.9	207
5	The microbiome in respiratory medicine: current challenges and future perspectives. <i>European Respiratory Journal</i> , 2017, 49, 1602086.	6.7	194
6	Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. <i>New England Journal of Medicine</i> , 2020, 383, 2127-2137.	27.0	158
7	Burden and risk factors for <i>Pseudomonas aeruginosa</i> community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , 2018, 52, 1701190.	6.7	122
8	Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 609-620.	5.6	120
9	Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2019, 68, 1482-1493.	5.8	116
10	Global initiative for meticillin-resistant <i>Staphylococcus aureus</i> pneumonia (GLIMP): an international, observational cohort study. <i>Lancet Infectious Diseases</i> , 2016, 16, 1364-1376.	9.1	109
11	Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 873-884.	10.7	99
12	The respiratory threat posed by multidrug resistant Gram-negative bacteria. <i>Respirology</i> , 2017, 22, 1288-1299.	2.3	84
13	Treatable traits in bronchiectasis. <i>European Respiratory Journal</i> , 2018, 52, 1801269.	6.7	84
14	Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. <i>Tuberculosis and Respiratory Diseases</i> , 2018, 81, 187.	1.8	70
15	Airway Bacterial Load and Inhaled Antibiotic Response in Bronchiectasis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 33-41.	5.6	70
16	Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 894-902.	5.6	67
17	Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations. <i>PLoS ONE</i> , 2015, 10, e0135199.	2.5	62
18	Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 391-401.	5.6	61

#	ARTICLE	IF	CITATIONS
19	Effects of glucocorticoids in ventilated piglets with severe pneumonia. <i>European Respiratory Journal</i> , 2008, 32, 1037-1046.	6.7	59
20	Hypocapnia and Hypercapnia Are Predictors for ICU Admission and Mortality in Hospitalized Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2012, 142, 1193-1199.	0.8	56
21	Identification of airway bacterial colonization by an electronic nose in Chronic Obstructive Pulmonary Disease. <i>Respiratory Medicine</i> , 2014, 108, 1608-1614.	2.9	55
22	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. <i>Cytokine</i> , 2016, 88, 267-273.	3.2	54
23	Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD. <i>Chest</i> , 2016, 150, 123-130.	0.8	50
24	A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation. <i>European Respiratory Journal</i> , 2019, 53, 1900303.	6.7	50
25	Corticosteroids in severe pneumonia. <i>European Respiratory Journal</i> , 2008, 32, 259-264.	6.7	49
26	Animal models of ventilator-associated pneumonia. <i>European Respiratory Journal</i> , 2009, 33, 182-188.	6.7	47
27	<i>Pseudomonas aeruginosa</i> in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study. <i>Respiration</i> , 2018, 96, 417-424.	2.6	45
28	Secreted mucins and airway bacterial colonization in non-CF bronchiectasis. <i>Respirology</i> , 2015, 20, 1082-1088.	2.3	43
29	Antimicrobial peptides, disease severity and exacerbations in bronchiectasis. <i>Thorax</i> , 2019, 74, 835-842.	5.6	43
30	Experimental Severe <i>Pseudomonas aeruginosa</i> Pneumonia and Antibiotic Therapy in Piglets Receiving Mechanical Ventilation. <i>Chest</i> , 2007, 132, 523-531.	0.8	41
31	Lung Function sequelae in COVID-19 Patients 3 Months After Hospital Discharge. <i>Archivos De Bronconeumologia</i> , 2021, 57, 59-61.	0.8	36
32	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). <i>Archivos De Bronconeumologia</i> , 2021, 57, 21-27.	0.8	35
33	Risk factors and antibiotic therapy in <i>Pseudomonas aeruginosa</i> community-acquired pneumonia. <i>Respirology</i> , 2015, 20, 660-666.	2.3	34
34	<i>Pseudomonas aeruginosa</i> resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. <i>Respirology</i> , 2016, 21, 1235-1242.	2.3	33
35	Prevalence and risk factors for <i>Enterobacteriaceae</i> in patients hospitalized with community-acquired pneumonia. <i>Respirology</i> , 2020, 25, 543-551.	2.3	31
36	C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON). <i>Archivos De Bronconeumologia</i> , 2021, 57, 21-27.	0.8	30

#	ARTICLE	IF	CITATIONS
37	Multidrug-resistant pathogens in patients with pneumonia coming from the community. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 219-226.	2.6	29
38	Experimental <i>Pseudomonas aeruginosa</i> pneumonia: evaluation of the associated inflammatory response. <i>European Respiratory Journal</i> , 2007, 30, 1167-1172.	6.7	28
39	Prior cardiovascular disease increases long-term mortality in COPD patients with pneumonia. <i>European Respiratory Journal</i> , 2014, 43, 36-42.	6.7	28
40	Relationship between the respiratory microbiome and the severity of airflow limitation, history of exacerbations and circulating eosinophils in COPD patients. <i>BMC Pulmonary Medicine</i> , 2019, 19, 112.	2.0	28
41	Pulmonary infections in non-HIV-immunocompromised patients. <i>Current Opinion in Pulmonary Medicine</i> , 2005, 11, 213-217.	2.6	27
42	Diagnostic challenges of bronchiectasis. <i>Respiratory Medicine</i> , 2016, 116, 70-77.	2.9	27
43	Nocardiosis pulmonar en pacientes con EPOC: características y factores pronósticos. <i>Archivos De Bronconeumología</i> , 2012, 48, 280-285.	0.8	26
44	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019, 60, 54-70.	2.2	26
45	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. <i>PLoS ONE</i> , 2017, 12, e0178022.	2.5	25
46	Predicting treatment failure in patients with community acquired pneumonia: a case-control study. <i>Respiratory Research</i> , 2014, 15, 75.	3.6	24
47	Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia. <i>Chest</i> , 2021, 159, 58-72.	0.8	24
48	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	6.5	23
49	Elevated plasma levels of epithelial and endothelial cell markers in COVID-19 survivors with reduced lung diffusing capacity six months after hospital discharge. <i>Respiratory Research</i> , 2022, 23, 37.	3.6	23
50	Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis. <i>Respiration</i> , 2018, 96, 406-416.	2.6	22
51	Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies. <i>European Respiratory Journal</i> , 2020, 56, 2000608.	6.7	22
52	Identification of <i>Pseudomonas aeruginosa</i> and airway bacterial colonization by an electronic nose in bronchiectasis. <i>Respiratory Medicine</i> , 2018, 136, 111-117.	2.9	21
53	Phenotypic Clustering in Non-Cystic Fibrosis Bronchiectasis Patients: The Role of Eosinophils in Disease Severity. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8431.	2.6	21
54	Heterogeneity of treatment response in bronchiectasis clinical trials. <i>European Respiratory Journal</i> , 2022, 59, 2100777.	6.7	21

#	ARTICLE	IF	CITATIONS
55	What is the Best Antimicrobial Treatment for Severe Community-Acquired Pneumonia (Including the Tj ETQq1 1 0.784314 rgBT /Ove North America, 2013, 27, 133-147.	5.1	20
56	Airway Mucin 2 Is Decreased in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. <i>Annals of the American Thoracic Society</i> , 2016, 13, 636-642.	3.2	19
57	Improving the 2007 Infectious Disease Society of America/American Thoracic Society severe community-acquired pneumonia criteria to predict intensive care unit admission. <i>Journal of Critical Care</i> , 2013, 28, 284-290.	2.2	18
58	The risk and outcomes of pneumonia in patients on inhaled corticosteroids. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 32, 130-136.	2.6	18
59	Anti-Pseudomonas aeruginosa IgG antibodies and chronic airway infection in bronchiectasis. <i>Respiratory Medicine</i> , 2017, 128, 1-6.	2.9	18
60	Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 1513-1525.	2.9	18
61	A Cluster Analysis of Bronchiectasis Patients Based on the Airway Immune Profile. <i>Chest</i> , 2021, 159, 1758-1767.	0.8	18
62	Protease-antiprotease imbalance in bronchiectasis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5996.	4.1	17
63	Experimental safety and efficacy evaluation of an extracorporeal pumpless artificial lung in providing respiratory support through the axillary vessels. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2007, 133, 339-345.e2.	0.8	16
64	An experimental model of pneumonia induced by methicillin-resistant <i>Staphylococcus aureus</i> in ventilated piglets. <i>European Respiratory Journal</i> , 2010, 36, 901-906.	6.7	16
65	Predicting ICU admission in community-acquired pneumonia: clinical scores and biomarkers. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 445-458.	3.1	16
66	Impact of Macrolide Therapy in Patients Hospitalized With <i>Pseudomonas aeruginosa</i> Community-Acquired Pneumonia. <i>Chest</i> , 2014, 145, 1114-1120.	0.8	16
67	Salivary immunity and lower respiratory tract infections in non-elite marathon runners. <i>PLoS ONE</i> , 2018, 13, e0206059.	2.5	16
68	COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation. <i>Chest</i> , 2020, 157, 824-833.	0.8	16
69	Sputum neutrophil elastase in bronchiectasis: a Southern European cohort study. <i>European Respiratory Journal</i> , 2020, 56, 2001702.	6.7	15
70	Atypical lymphoid cells circulating in blood in COVID-19 infection: morphology, immunophenotype and prognosis value. <i>Journal of Clinical Pathology</i> , 2022, 75, 104-111.	2.0	14
71	Biomarcadores biológicos en las enfermedades respiratorias. <i>Archivos De Bronconeumología</i> , 2022, 58, 323-333.	0.8	14
72	Role of respiratory intermediate care units during the SARS-CoV-2 pandemic. <i>BMC Pulmonary Medicine</i> , 2021, 21, 228.	2.0	12

#	ARTICLE	IF	CITATIONS
73	Associated inflammatory response in pneumonia: role of adjunctive therapy with glucocorticoids. <i>Current Opinion in Infectious Diseases</i> , 2006, 19, 179-184.	3.1	11
74	Effects of Inhaled Corticosteroids on Pneumonia Severity and Antimicrobial Resistance. <i>Respiratory Care</i> , 2013, 58, 1489-1494.	1.6	11
75	Biomarkers in community-acquired pneumonia: still searching for the one. <i>European Respiratory Journal</i> , 2019, 53, 1802469.	6.7	11
76	[Translated article] Biological Biomarkers in Respiratory Diseases. <i>Archivos De Bronconeumologia</i> , 2022, 58, T323-T333.	0.8	11
77	Nonantibiotic Adjunctive Therapies for Community-Acquired Pneumonia (Corticosteroids and Beyond): Where Are We with Them?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 913-922.	2.1	10
78	Low birth weight as a potential risk factor for severe COVID-19 in adults. <i>Scientific Reports</i> , 2021, 11, 2909.	3.3	10
79	High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis. <i>European Respiratory Journal</i> , 2017, 50, 1700013.	6.7	9
80	Reduced airway levels of fatty-acid binding protein 4 in COPD: relationship with airway infection and disease severity. <i>Respiratory Research</i> , 2020, 21, 21.	3.6	9
81	Add-on inhaled budesonide in the treatment of hospitalised patients with COVID-19: a randomised clinical trial. <i>European Respiratory Journal</i> , 2022, 59, 2103036.	6.7	9
82	Nosocomial pneumonia in immunosuppressed patients1. <i>Infectious Disease Clinics of North America</i> , 2003, 17, 785-800.	5.1	8
83	Optimal Positive End-Expiratory Pressure During Pumpless Extracorporeal Lung Membrane Support. <i>Artificial Organs</i> , 2008, 32, 885-890.	1.9	8
84	The Paradoxical Effect on Pneumonia of Chronic Inhaled Corticosteroids. <i>Clinical Pulmonary Medicine</i> , 2013, 20, 6-10.	0.3	8
85	Chromogranin A levels and mortality in patients with severe sepsis. <i>Biomarkers</i> , 2015, 20, 171-176.	1.9	8
86	Asthma with bronchial hypersecretion: expression of mucins and toll-like receptors in sputum and blood. <i>Journal of Asthma and Allergy</i> , 2017, Volume10, 269-276.	3.4	8
87	Positive end expiratory pressure in acute hypoxemic respiratory failure due to community acquired pneumonia: do we need a personalized approach?. <i>PeerJ</i> , 2018, 6, e4211.	2.0	8
88	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. <i>Journal of Clinical Medicine</i> , 2019, 8, 1461.	2.4	7
89	Future Directions in Bronchiectasis Research. <i>Clinics in Chest Medicine</i> , 2022, 43, 179-187.	2.1	7
90	Blood Neutrophil Counts Define Specific Clusters of Bronchiectasis Patients: A Hint to Differential Clinical Phenotypes. <i>Biomedicines</i> , 2022, 10, 1044.	3.2	7

#	ARTICLE	IF	CITATIONS
91	Evaluation of the IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia. Hospital Practice (1995), 2012, 40, 158-164.	1.0	6
92	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Annals of the American Thoracic Society, 2021, 18, 1316-1325.	3.2	6
93	Breath analysis using electronic nose and gas chromatography-mass spectrometry: A pilot study on bronchial infections in bronchiectasis. Clinica Chimica Acta, 2022, 526, 6-13.	1.1	6
94	Effects of a polysaccharide-based multi-ingredient supplement on salivary immunity in non-elite marathon runners. Journal of the International Society of Sports Nutrition, 2019, 16, 14.	3.9	5
95	Differences in Nutritional Status and Inflammatory Biomarkers between Female and Male Patients with Bronchiectasis: A Large-Cohort Study. Biomedicines, 2021, 9, 905.	3.2	5
96	New biomarkers in community-acquired pneumonia: another step in improving outcome prediction. Respirology, 2017, 22, 416-417.	2.3	4
97	Happy Birthday, Bronchiectasis: 200 Years of Targeting Mucus. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 639-640.	5.6	4
98	Systemic Inflammatory Biomarkers Define Specific Clusters in Patients with Bronchiectasis: A Large-Cohort Study. Biomedicines, 2022, 10, 225.	3.2	4
99	Reducing <i>Pseudomonas</i> sputum density in bronchiectasis. European Respiratory Journal, 2021, 57, 2003390.	6.7	3
100	Severity assessment tools in CAP. , 2014, , 88-104.		3
101	Relationship Between Severity Classification of Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Clinical Outcomes in Hospitalized Patients. Cureus, 2017, 9, e988.	0.5	3
102	Impact of prior systemic corticosteroid use in patients admitted with community-acquired pneumonia. Therapeutic Advances in Respiratory Disease, 2012, 6, 323-330.	2.6	2
103	Migratory Pulmonary Nodules in a Patient With Ulcerative Colitis. Archivos De Bronconeumologia, 2015, 51, 303-304.	0.8	2
104	Nódulos pulmonares migratorios en paciente con colitis ulcerosa. Archivos De Bronconeumologia, 2015, 51, 303-304.	0.8	2
105	Pathophysiology, Immunology, and Histopathology of Bronchiectasis. , 2018, , 51-64.		2
106	Noninvasive Ventilation Weaning in Acute Hypercapnic Respiratory Failure due to COPD Exacerbation: A Real-Life Observational Study. Canadian Respiratory Journal, 2019, 2019, 1-10.	1.6	2
107	[Translated article] Study of diffuse interstitial lung disease with the analysis of volatile particles in exhaled air. Archivos De Bronconeumologia, 2022, 58, T99-T101.	0.8	2
108	Corticosteroids for pneumonia: Are we there yet?. Respirology, 2013, 18, 199-200.	2.3	1

#	ARTICLE	IF	CITATIONS
109	Antiplatelets Improve Survival Among Critically Ill Mechanically Ventilated Patients. <i>Chest</i> , 2014, 146, 500A.	0.8	1
110	Reply: Measuring Airway Mucin 2 in Patients with Severe Chronic Obstructive Pulmonary Disease with Bacterial Colonization. <i>Annals of the American Thoracic Society</i> , 2016, 13, 2104-2105.	3.2	1
111	Estudio de la enfermedad pulmonar intersticial difusa mediante el análisis de partículas volátiles en el aire exhalado. <i>Archivos De Bronconeumología</i> , 2022, 58, 99-101.	0.8	1
112	SARS-CoV-2 pneumonia and atypical lymphocyte morphology in pleural fluid. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	1.3	1
113	Predicting Early Hospital Readmissions in COPD Patients Using an Electronic Nose. <i>Archivos De Bronconeumología</i> , 2022, 58, 663-665.	0.8	1
114	Corticoides en la neumonía: argumentos a favor. <i>Archivos De Bronconeumología</i> , 2011, 47, 222-223.	0.8	0
115	Immunological Response to <i>Mycoplasma pneumoniae</i> (Mp) and CARDS Toxin Is Related to Severe Histological Inflammation and a TH2 Response in a Primate Model. <i>Chest</i> , 2012, 142, 192A.	0.8	0
116	Monotherapy vs Combination Antibiotic Therapy for Patients Admitted for <i>Pseudomonas</i> Community-Acquired Pneumonia. <i>Chest</i> , 2013, 144, 389A.	0.8	0
117	Procalcitonin Does Not Decrease Antibiotic Duration in an Antimicrobial Stewardship Driven MICU. <i>Chest</i> , 2014, 146, 215A.	0.8	0
118	Hospitalized AECOPD Patients Not Treated With Antibiotic Have Higher Rates of 1-Year Pneumonia Related Hospitalization. <i>Chest</i> , 2014, 146, 65A.	0.8	0
119	Clinical Efficacy of Azithromycin in Patients With Severe Sepsis: Open Label Pilot Randomized Controlled Trial. <i>Chest</i> , 2014, 145, 151A.	0.8	0
120	Response to: Comment on "Noninvasive Ventilation Weaning in Acute Hypercapnic Respiratory Failure due to COPD Exacerbation: A Real-Life Observational Study". <i>Canadian Respiratory Journal</i> , 2019, 2019, 1-2.	1.6	0
121	Long-Term Antibiotics in Bronchiectasis. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021, 42, 606-615.	2.1	0
122	Corticoids in Severe Pneumonia. , 2008, , 45-51.		0
123	Improving Appropriate Utilization of Procalcitonin in Critically Ill Medical Patients. <i>Chest</i> , 2012, 142, 364A.	0.8	0
124	Chronic bronchitis: a risk factor for bronchial infection. , 2013, , 18-26.		0
125	Study of diffuse interstitial lung disease with the analysis of volatile particles in exhaled air. <i>Archivos De Bronconeumología</i> , 2021, , .	0.8	0
126	Inflamación local y sistémica en bronquiectasias. Endotipos y biomarcadores. <i>Open Respiratory Archives</i> , 2020, 2, 235-241.	0.1	0

#	ARTICLE	IF	CITATIONS
127	Early hospital readmission increases short and long - term mortality in patients with interstitial lung disease. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021021.	0.2	0
128	[Translated article] Histology Study of Postmortem Lung Biopsies in Patients With Covid-19 Pneumonia. <i>Archivos De Bronconeumologia</i> , 2022, 58, T444-T447.	0.8	0